Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Corrigendum to "Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer": [ESMO Open 3 (2018) e000375].
ESMO Open. 2023 Apr;8(2):101185. doi: 10.1016/j.esmoop.2023.101185. Epub 2023 Mar 1.
ESMO Open. 2023.
PMID: 36868156
Free PMC article.
No abstract available.
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.
Fumet JD, Isambert N, Hervieu A, Zanetta S, Guion JF, Hennequin A, Rederstorff E, Bertaut A, Ghiringhelli F.
Fumet JD, et al. Among authors: guion jf.
ESMO Open. 2018 Jun 19;3(4):e000375. doi: 10.1136/esmoopen-2018-000375. eCollection 2018.
ESMO Open. 2018.
PMID: 29942666
Free PMC article.
Item in Clipboard
Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale.
Ledys F, Derangère V, Réda M, Guion JF, Milliex R, Roux V, Limagne E, Arnould L, Bengrine L, Ghiringhelli F, Rébé C.
Ledys F, et al. Among authors: guion jf.
Adv Ther. 2019 Jun;36(6):1480-1484. doi: 10.1007/s12325-019-00949-y. Epub 2019 Apr 12.
Adv Ther. 2019.
PMID: 30980281
Item in Clipboard
Cite
Cite